Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03662282 · ClinicalTrials.gov registry record · Phase 3

Omegaven as Alternative Parenteral Fat Nutrition

A Phase 3 study, sponsored by University of South Florida.

Completed
Registry status
Phase 3
Development phase
2
Enrollment target

NCT03662282 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03662282, a Phase 3 study, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
Phase 3
Development phase
2 participants
Enrollment target

Study Summary

To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis

Interventions

  • DRUG Omegaven

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2018-10-23
Est. Completion 2019-01-07
Phase Phase 3

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT03662282

The ClinicalTrials.gov registry entry for NCT03662282 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Omegaven is the first listed.

NCT03662282 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03662282 about?

NCT03662282 is a clinical study titled "Omegaven as Alternative Parenteral Fat Nutrition". To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis

What is the current status of trial NCT03662282?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2018-10-23. Estimated completion is 2019-01-07.

What interventions are being tested in trial NCT03662282?

The interventions under investigation include: Omegaven (DRUG).

Who is sponsoring clinical trial NCT03662282?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.